FDA approves first non-opioid to treat withdrawal symptoms

Federal regulators have approved the first nonopioid treatment to ease withdrawal from quitting addictive opioids.

The U.S. Food and Drug Administration expedited approval of Lucemyra to help combat the U.S. opioid epidemic. Two-thirds of drug overdose deaths in 2016 involved opioids, mostly fentanyl, heroin and prescription painkillers.

The pill was approved to treat adults for up to two weeks for common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation. It is not an addiction medicine but can be part of a longer-term treatment plan, according to the FDA.

Related

health

healthOpioid crisis makes more organs available

People going through detox are usually given a safer opioid medicine like methadone, which eases the cravings without an intense high.

“The fear of experiencing withdrawal symptoms often prevents those suffering from opioid addiction from seeking help,” FDA Commissioner Dr. Scott Gottlieb said in a statement.

In two studies of 866 adults, those given Lucemyra reported less severe withdrawal symptoms when they abruptly stopped taking opioids, compared to those who were given dummy pills.

For Subscribers

FOR SUBSCRIBERSEurope’s protests are about more than schools. They are a generational roar.

FOR SUBSCRIBERSTrump is desperate to bring gas prices down. The solution might be in India.

FOR SUBSCRIBERSNew AI tool for voters offers a specialized chatbot to explain your ballot

FOR SUBSCRIBERSWhat the rural data center boom looks like, from the people who have lived through it

FOR SUBSCRIBERSInteractive map: How far do you live from the nearest data center?

FOR SUBSCRIBERSiPhone Duo review: The good, bad and the buggy

FOR SUBSCRIBERSAnger over rising prices could be decisive in Alaska’s unusually close Senate race

FOR SUBSCRIBERSDOJ weighs election litigation against more states

FOR SUBSCRIBERSGOP Senate hopeful Ashley Hinson balances standing by Trump and standing up to him in Iowa

FOR SUBSCRIBERSInside the reopened U.S. Embassy in Caracas

FOR SUBSCRIBERSAIPAC shifts tactics amid voter frustration with Israel

FOR SUBSCRIBERSThe viral attack ad featuring an estranged mother

FOR SUBSCRIBERSU.S. troops and diplomats evacuating Middle East posts, sources say

FOR SUBSCRIBERSBogus trans youth brochure rattles Texas voters

FOR SUBSCRIBERSWho knew a basket could be sexy? How ‘Wicker’ became fall’s surprise must-see

Slide 1 of 1

Side effects included low blood pressure, dizziness, sleepiness, slow heart rate and, in a few people, fainting.

For Subscribers

FOR SUBSCRIBERSEurope’s protests are about more than schools. They are a generational roar.

FOR SUBSCRIBERSTrump is desperate to bring gas prices down. The solution might be in India.

FOR SUBSCRIBERSNew AI tool for voters offers a specialized chatbot to explain your ballot

FOR SUBSCRIBERSWhat the rural data center boom looks like, from the people who have lived through it

FOR SUBSCRIBERSInteractive map: How far do you live from the nearest data center?

FOR SUBSCRIBERSiPhone Duo review: The good, bad and the buggy

FOR SUBSCRIBERSAnger over rising prices could be decisive in Alaska’s unusually close Senate race

FOR SUBSCRIBERSDOJ weighs election litigation against more states

FOR SUBSCRIBERSGOP Senate hopeful Ashley Hinson balances standing by Trump and standing up to him in Iowa

FOR SUBSCRIBERSInside the reopened U.S. Embassy in Caracas

FOR SUBSCRIBERSAIPAC shifts tactics amid voter frustration with Israel

FOR SUBSCRIBERSThe viral attack ad featuring an estranged mother

FOR SUBSCRIBERSU.S. troops and diplomats evacuating Middle East posts, sources say

FOR SUBSCRIBERSBogus trans youth brochure rattles Texas voters

FOR SUBSCRIBERSWho knew a basket could be sexy? How ‘Wicker’ became fall’s surprise must-see

Slide 1 of 1

The FDA is requiring drugmaker US WorldMeds of Louisville, Kentucky, to conduct more studies in teens and newborns of opioid-addicted mothers and for possible longer-term use in people tapering off opioids.

Privately held US WorldMeds said it had not yet set a price for Lucemyra.